Akari Therapeutics (AKTX) Projected to Announce Quarterly Earnings on Tuesday

Akari Therapeutics (NASDAQ:AKTX) is expected to announce its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect the company to announce earnings of ($1.04) per share for the quarter. Parties can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 18, 2026 at 4:00 PM ET.

Akari Therapeutics Stock Up 7.6%

Shares of AKTX opened at $7.53 on Tuesday. Akari Therapeutics has a 52-week low of $3.02 and a 52-week high of $49.60. The stock has a 50 day moving average price of $11.23 and a 200 day moving average price of $9.12.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Wall Street Zen cut shares of Akari Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 25th. Maxim Group raised Akari Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a report on Monday, July 20th. Finally, Weiss Ratings upgraded Akari Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.33.

Institutional Trading of Akari Therapeutics

A hedge fund recently bought a new position in Akari Therapeutics stock. Armistice Capital LLC bought a new stake in Akari Therapeutics PLC (NASDAQ:AKTX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned about 5.95% of Akari Therapeutics at the end of the most recent quarter. Institutional investors own 5.06% of the company’s stock.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.